These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7865675)

  • 1. Course of thrombin activation markers in patients implanted with Palmaz-Schatz stents: first experiences with a post-interventional anticoagulation regimen.
    Haushofer A; Halbmayer WM; Dittel M; Prachar H; Mlczoch J; Fischer M
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):697-706. PubMed ID: 7865675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].
    Dittel M; Haushofer A; Spiel R; Halbmayer WM; Prachar H; Fischer M; Mlczoch J
    Z Kardiol; 1995 Jan; 84(1):22-9. PubMed ID: 7863710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance of anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring prothrombin and prothrombin fragment 1 + 2.
    Haude M; Hafner G; Jablonka A; Rupprecht HJ; Prellwitz W; Meyer J; Erbel R
    Am Heart J; 1995 Aug; 130(2):228-38. PubMed ID: 7631600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring prothrombin fragment 1 + 2 during initiation of oral anticoagulant therapy after intracoronary stenting.
    Hafner G; Swars H; Erbel R; Ehrenthal W; Rupprecht HJ; Lotz J; Meyer J; Prellwitz W
    Ann Hematol; 1992 Aug; 65(2):83-7. PubMed ID: 1511062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.
    Gawaz M; Neumann FJ; Ott I; May A; Schömig A
    Circulation; 1996 Aug; 94(3):279-85. PubMed ID: 8759067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.
    Fernández-Avilés F; Alonso JJ; Durán JM; Gimeno F; Muñoz JC; de la Fuente L; San Román JA
    J Am Coll Cardiol; 1996 Jan; 27(1):22-9. PubMed ID: 8522699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
    Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No subacute thrombosis and femoral bleeding complications under full anticoagulation in 150 consecutive patients receiving non-heparin-coated intracoronary Palmaz-Schatz stents.
    Lee SW; Chen MZ; Chan HW; Lam L; Guo JX; Mao JM; Lam KK; Guo LJ; Li HY; Chan KK
    Am Heart J; 1996 Dec; 132(6):1135-46. PubMed ID: 8969564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis.
    Kienast J; Thompson SG; Raskino C; Pelzer H; Fechtrup C; Ostermann H; van de Loo J
    Thromb Haemost; 1993 Oct; 70(4):550-3. PubMed ID: 8115978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation.
    Bruhn HD; Zurborn KH
    J Heart Valve Dis; 1995 Mar; 4(2):138-40. PubMed ID: 8556173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
    Schömig A; Neumann FJ; Walter H; Schühlen H; Hadamitzky M; Zitzmann-Roth EM; Dirschinger J; Hausleiter J; Blasini R; Schmitt C; Alt E; Kastrati A
    J Am Coll Cardiol; 1997 Jan; 29(1):28-34. PubMed ID: 8996291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between prothrombin activation fragment (F1.2), cerebral ischemia (S-100beta) and international normalized ratio (INR) in patients with ventricular assisted devices.
    Joshi A; Magder LS; Kon Z; Kallam S; Kwon M; Sangrampurkar R; Pierson R; Poston R
    Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):323-7. PubMed ID: 17669856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting.
    Neumann FJ; Gawaz M; Ott I; May A; Mössmer G; Schömig A
    J Am Coll Cardiol; 1996 Jan; 27(1):15-21. PubMed ID: 8522689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prothrombin fragment F1 + 2 concentrations for monitoring anticoagulation therapy with heparin.
    Brack MJ; More RS; Hubner PJ; Gershlick AH
    Int J Cardiol; 1993 Jan; 38(1):57-61. PubMed ID: 8444502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Measurement of prothrombin fragment F1+2 for monitoring the anticoagulant effect of phenprocoumon].
    Bruhn HD; Zurborn KH
    Dtsch Med Wochenschr; 1993 Jul; 118(26):967-70. PubMed ID: 8519230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation.
    Bertram M; Bonsanto M; Hacke W; Schwab S
    J Neurol; 2000 Mar; 247(3):209-14. PubMed ID: 10787117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.